SEC v. Kin-Hung Peony Yu, No. LR-26394, Northern District of California (Sept. 5, 2025) — Press Release
raw: Kin-Hung Peony Yu
Kin-Hung Peony Yu, No. 3:25-cv-07593 (Sept. 5, 2025)
summary
Former FibroGen CMO Dr. Kin-Hung Peony Yu was charged by the SEC for misleading investors about roxadustat's cardiovascular safety through manipulated clinical trial analyses.
paragraph
Dr. Kin-Hung Peony Yu faces charges for violating antifraud provisions of the Securities Act of 1933 and the Securities Exchange Act of 1934. The SEC alleges she manipulated roxadustat clinical trial data between November 2019 and March 2021 to falsely claim superiority over existing treatments. The litigation seeks permanent injunctive relief, an officer-and-director bar, disgorgement of ill-gotten gains, and civil penalties.
narrative
The SEC has charged Dr. Kin-Hung Peony Yu, the former Chief Medical Officer of FibroGen, Inc., for making false and misleading claims regarding the cardiovascular safety of the drug candidate roxadustat. Between November 2019 and March 2021, Dr. Yu allegedly reverse-engineered clinical trial results to make roxadustat appear superior to existing treatments when initial data showed it was merely comparable. These misleading claims were disseminated through SEC filings, earnings calls, industry presentations, and published articles. Following her departure, FibroGen management issued a corrective disclosure in April 2021 admitting the results were based on post-hoc changes. Dr. Yu is charged with violating antifraud provisions of the Securities Act of 1933 and the Securities Exchange Act of 1934. The SEC is seeking permanent injunctive relief, an officer-and-director bar, disgorgement of gains, and civil penalties.
Classified accounting-fraud(confidence 95%). EDGAR detection: forms 10-K/10-Q/8-K/NT 10-K· recall 80% / precision 48%. detection rule →
Statutes
Parties
Securities And Exchange CommissionYu
Keywords
kin-hung peonysecurities exchangeresultsexchange commissionfalse misleadingsecuritiessecfibrogenkin-hungpeonyexchangetreatmentchief medicalmedical officermisleading claims
Exhibits & Attached Documents (1)
Extracted insights
Entities 8
- person Daniel J. Maher
- person Edward B. Gerard
- person permanent injunctive relief
- agency sec's investigation
- agency sec's litigation
- agency Securities and Exchange Commission
- organization Securities and Exchange Commission
- person violating antifraud provisions
Triples 10
- Securities And Exchange Commission filed charges Dr. Kin-Hung Peony Yu
- Dr. Kin-Hung Peony Yu made false claims about roxadustat's cardiovascular safety
- Dr. Kin-Hung Peony Yu directed changes to initial study results
- FibroGen Inc. issued corrective disclosure about roxadustat's results
- Securities And Exchange Commission seeks relief permanent injunctive relief
- Securities And Exchange Commission charges Dr. Yu with violating antifraud provisions
- Dr. Kin-Hung Peony Yu violated Section 17(a)(2) of the Securities Act of 1933
- Dr. Kin-Hung Peony Yu violated Section 10(b) of the Securities Exchange Act of 1934
- Edward B. Gerard conducted investigation SEC's investigation
- Daniel J. Maher will lead litigation SEC's litigation
PDF (from attached: complaint)
Text layers
Extracted body text (2,506c)
U.S. SECURITIES AND EXCHANGE COMMISSION Litigation Release No. 26394 / Sept. 10, 2025 Securities and Exchange Commission v. Kin-Hung Peony Yu, No. 3:25-cv-07593 (N.D. Cal. filed Sept. 5, 2025) SEC Charges Former FibroGen Chief Medical Officer for False and Misleading Claims about Clinical Trial Results On September 5, 2025, the Securities and Exchange Commission filed charges against Dr. Kin-Hung Peony Yu, the former Chief Medical Officer of FibroGen, Inc., for allegedly making false and misleading statements about the cardiovascular safety of FibroGen’s then-primary drug candidate, roxadustat. According to the SEC’s complaint, during the period from November 2019 to March 2021, Dr. Yu misled investors with claims that the results of key studies established that roxadustat, a potential therapy for the treatment of anemia in chronic kidney disease patients, was superior in cardiovascular safety to the primary existing treatment. But Dr. Yu allegedly failed to disclose to investors that she had reverse engineered the results. Specifically, the complaint alleges that the initial analyses showed the treatment was, at best, comparable to the existing treatment and that, after viewing the initial results, Dr. Yu directed changes to make roxadustat appear superior. Dr. Yu is alleged to have made the false and misleading claims in a range of forums, including a high-profile industry presentation and accompanying press release, multiple SEC filings, an earnings call, and a published article in a leading industry journal. After Dr. Yu’s departure, new FibroGen management issued a corrective disclosure in an April 6, 2021 press release, in which they admitted that FibroGen’s previously disclosed results were based on post-hoc changes to the analyses and disclosed the less favorable initial results. The SEC's complaint, filed in the U.S. District Court for the Northern District of California, charges Dr. Yu with violating the antifraud provisions of Section 17(a)(2) of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5(b) thereunder. The complaint seeks permanent injunctive relief, an officer-and-director bar, disgorgement of ill-gotten gains plus prejudgment interest, and a civil penalty. The SEC’s investigation was conducted by Edward B. Gerard and assisted by Kelly V. Silverman. The matter was supervised by J. Lee Buck II and Pei Y. Chung. The SEC’s litigation will be led by Daniel J. Maher and supervised by David A. Nasse.
OCR text (2,506c · html-text · 99% conf)
U.S. SECURITIES AND EXCHANGE COMMISSION Litigation Release No. 26394 / Sept. 10, 2025 Securities and Exchange Commission v. Kin-Hung Peony Yu, No. 3:25-cv-07593 (N.D. Cal. filed Sept. 5, 2025) SEC Charges Former FibroGen Chief Medical Officer for False and Misleading Claims about Clinical Trial Results On September 5, 2025, the Securities and Exchange Commission filed charges against Dr. Kin-Hung Peony Yu, the former Chief Medical Officer of FibroGen, Inc., for allegedly making false and misleading statements about the cardiovascular safety of FibroGen’s then-primary drug candidate, roxadustat. According to the SEC’s complaint, during the period from November 2019 to March 2021, Dr. Yu misled investors with claims that the results of key studies established that roxadustat, a potential therapy for the treatment of anemia in chronic kidney disease patients, was superior in cardiovascular safety to the primary existing treatment. But Dr. Yu allegedly failed to disclose to investors that she had reverse engineered the results. Specifically, the complaint alleges that the initial analyses showed the treatment was, at best, comparable to the existing treatment and that, after viewing the initial results, Dr. Yu directed changes to make roxadustat appear superior. Dr. Yu is alleged to have made the false and misleading claims in a range of forums, including a high-profile industry presentation and accompanying press release, multiple SEC filings, an earnings call, and a published article in a leading industry journal. After Dr. Yu’s departure, new FibroGen management issued a corrective disclosure in an April 6, 2021 press release, in which they admitted that FibroGen’s previously disclosed results were based on post-hoc changes to the analyses and disclosed the less favorable initial results. The SEC's complaint, filed in the U.S. District Court for the Northern District of California, charges Dr. Yu with violating the antifraud provisions of Section 17(a)(2) of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5(b) thereunder. The complaint seeks permanent injunctive relief, an officer-and-director bar, disgorgement of ill-gotten gains plus prejudgment interest, and a civil penalty. The SEC’s investigation was conducted by Edward B. Gerard and assisted by Kelly V. Silverman. The matter was supervised by J. Lee Buck II and Pei Y. Chung. The SEC’s litigation will be led by Daniel J. Maher and supervised by David A. Nasse.